DEFEND (Durable response therapy Evaluation For Early or New-onset type 1 Diabetes) is another of those ultra-cute acronyms for a research study. The study is evaluating a drug called otelixizumab to see if it helps folks with type 1 diabetes. Details of the study can be found both at the DEFEND web...
-
allenxvr
Alan S
Monday, February 23, 2009 at 01:04 AM -
DEFEND
Kim Benjet
Monday, February 23, 2009 at 10:44 AMGreat blog, Bill! Thanks for clarifying this worthy study . . .with its unfortunately less than desirable ad campaign.
Kim
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
What the community is saying...
SGLT2 inhibitors -- an upcoming class of medications for diabetes
Posted 03/15 Comments (2)
Sodium-glucose transporter-2 (SGLT2) is the name of a...
I concur with your concern. I would not care if this person was up-front and clear as to who they are and who they represent. But there is no good reason for the secrecy.
I've noticed "allenxvr" on several different sites and also on usenet, on misc.health.diabetes and alt.support.diabetes. On usenet the person is more often canvassing for participants in studies. For example here is a recent post on alt.support.diabetes:
Have you been recently diagnosed with Type 1 Diabetes?
and another on misc.health.diabetes:
Study of Oral Insulin for Type 2 Diabetes Patients
They have been using this pseudonym for quite a while and it is not just restricted to diabetes groups. The Google groups activity profile is here: allenxvr
Cheers, Alan